Form 4: Galectin Therapeutics Director Eldred Kary Acquires Additional Shares

Director Eldred Kary reports acquisition of 500 shares of Galectin Therapeutics, increasing direct and indirect holdings.

Summary

• On October 23, 2024, Eldred Kary, a director of Galectin Therapeutics Inc., acquired 500 shares of common stock at a price of $2.6 per share.
• Following this transaction, Kary directly owns 50,213 shares of common stock.
• Kary also indirectly owns 2,425 shares as UTMA custodian for a minor child and 2,000 shares held in trust.
• The reporting person disclaims beneficial ownership of these securities held as custodian or in trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The purchase could be seen as slightly positive, but without further context, it's difficult to gauge the true sentiment.

Positives

• The director's purchase could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding 10% or more of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment.

Key Dates